Menu Close

Samsara Therapeutics Establishes Scientific Advisory Board

Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics

Samsara SAB
Oxford, UK and Boston, US, 06 January 2022: Samsara Therapeutics Inc. (Samsara), a discovery-stage biotech with a world-leading screening platform for inducers of autophagy and a growing pipeline of small molecule neurodegeneration and rare disease therapeutics, today announced the formation of its scientific advisory board (SAB) with the appointment of four distinguished leaders in the areas of neurodegeneration, rare genetic disease, and protein sciences. Dr Michael Schlossmacher, Prof Susan Perlman, Prof Ed Tate and Prof Christian Behl will help the Company advance several series of novel compounds into development for Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and certain rare genetic conditions.

The new SAB members will join Guido Kroemer MD, PhD, Scientific co-founder of Samsara Therapeutics, a highly cited and well-renowned leader in cell biology and the process of autophagy.

Jens Eckstein PhD, Chairman, Samsara Therapeutics and Managing Partner, Apollo Health Ventures, commented: “The assembly of this distinguished group of key opinion leaders will allow Samsara to develop its clinical strategy for an emerging pipeline of novel therapeutics in currently intractable diseases. Their expertise and knowledge in the field of neurodegeneration, rare genetic disease, and protein science will be vital in driving the development of pioneering compounds to target key disease areas.”

Peter Hamley PhD MBA, Chief Scientific Officer, Samsara Therapeutics, said: “We look forward to working closely with the talented members of our new SAB to drive the clinical development of our promising pipeline while ensuring that we build on the early success of our technology platform. Together with this exceptional team of experts, we will continue to advance the discovery of neurodegeneration and rare genetic disease therapeutics.”

For more information about Samsara’s SAB, please visit:

Media contacts:

Michelle Ricketts PhD

Zyme Communications


Tel: +44 (0)778 9053 885